[Treatment of epidemic keratoconjunctivitis with ABOB. Clinical and laboratory investigations (author's transl)].
In an epidemic of viral keratoconjunctivitis in Bulgaria in 1972, caused by adenovirus 9, we applied ABOB in 1 percent solution topically in 120 of all 151 observed patients. When the treatment could be begun in first 3-5 days of the disease, a very favourable curing effect was noted. In most of the patients occurred a significant subjective improvement. The effect was most pronounced upon the course of ther keratitis stage. When ABOB was applied early, the observed keratitis was lighter, with slight visual impairment (with a duration of more than one month in 14.4 percent of the patients, as opposed to 57.3 percent in a placebo group), with quicker epithelialization of corneal erosions and, as a result, with fewer residual corneal opacities.
D000257:Adenoviridae Infections / Q000150:complications / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001645:Biguanides / Q000627:therapeutic use*; D003318:Corneal Opacity / Q000150:complications; D006801:Humans; D007637:Keratoconjunctivitis / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010919:Placebos; D013997:Time Factors; D014786:Vision Disorders / Q000150:complications
D000998:Antiviral Agents; D001645:Biguanides; D010919:Placebos
Uber die Behandlung der epidemischen Keratokonjunktivitis mit ABOB Klinische und Laboruntersuchungen